UTMD vs LMAT

For growth investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger pick with 13. 5% revenue growth year-over-year, versus -5. 8% for Utah Medical Products, Inc. (UTMD). Utah Medical Products, Inc. (UTMD) offers the better valuation at 18. 5x trailing P/E (10. 2x forward), making it the more compelling value choice. Analysts rate LeMaitre Vascular, Inc. (LMAT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Utah Medical Products, Inc.

(UTMD) is the cheapest at 18. 5x versus LeMaitre Vascular, Inc. at 43. 7x. On forward P/E, Utah Medical Products, Inc. is actually cheaper at 10. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: LeMaitre Vascular, Inc. wins at 1. 96x versus Utah Medical Products, Inc. 's 2. 99x — a reasonable growth-adjusted valuation.

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +121. 9%, compared to -17. 8% for Utah Medical Products, Inc. (UTMD). Over 10 years, the gap is even starker: LMAT returned +619. 5% versus UTMD's +18. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus LeMaitre Vascular, Inc. 's 0. 57β — meaning LMAT is approximately 3% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 47% for LeMaitre Vascular, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LeMaitre Vascular, Inc.

(LMAT) is pulling ahead at 13. 5% versus -5. 8% for Utah Medical Products, Inc. (UTMD). On earnings-per-share growth, the picture is similar: LeMaitre Vascular, Inc. grew EPS 30. 6% year-over-year, compared to -12. 1% for Utah Medical Products, Inc.. Over a 3-year CAGR, LMAT leads at 15. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus 23. 1% for LeMaitre Vascular, Inc. — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus 27. 2% for LMAT. At the gross margin level — before operating expenses — LMAT leads at 71. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, LeMaitre Vascular, Inc. (LMAT) is the more undervalued stock at a PEG of 1. 96x versus Utah Medical Products, Inc. 's 2. 99x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Utah Medical Products, Inc. (UTMD) trades at 10. 2x forward P/E versus 38. 0x for LeMaitre Vascular, Inc. — 27. 7x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Utah Medical Products, Inc. (UTMD) offers the highest yield at 1. 9%, versus 0. 7% for LeMaitre Vascular, Inc. (LMAT).

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +619. 5% 10Y return). Both have compounded well over 10 years (LMAT: +619. 5%, UTMD: +18. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.